Etude de l'AG du 28/06/2017
Tout comme l’année dernière, le rapport spécial des commissaires aux comptes portant sur les conventions et engagements réglementés n'est pas disponible dans les délais, ce qui constitue un manquement non négligeable aux devoirs d'information des actionnaires. Par conséquent, nous recommandons l'opposition à la résolution 4.
Par ailleurs, la société ne présente pas non plus les politiques de rémunération des dirigeants pour 2017. On notera à ce sujet qu’interrogée par Proxinvest la société n’a pas daigné nous répondre, ce qui, là encore, montre le peu de cas que la société fait de ses actionnaires.
Enfin, on relèvera qu’ « Au 31 décembre 2016, le nombre d’actions supplémentaires susceptibles d’être émises est de 17.693.707 » ; cela représente 42,6% du capital et est l’une des dilutions potentielles les plus importantes observées sur la place parisienne.
AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signaling patways within cells. Co. targets diseases such as cancer, inflammatory diseases and central nervous system diseases, in both human and veterinary medecines. Co. has developed its own portfolio of molecules including masitinib, which has already been registered in Europe and the U.S.A. and is pursuing five phase 3 studies in human medecine, including studies in pancreatic cancer, GIST, metastatic melanoma, and studies in mastocytosis and severe persistent asthma.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
- Proxy reports
- Definition and monitoring of client customized voting guidelines
- Corporate Governance Data and Rating
- Thematic research
- Engagement support
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.